Zydus introduces cancer treatment IBYRA in India, making advanced therapy accessible

In a groundbreaking development for cancer treatment in India, Zydus Lifesciences has launched Olaparib under the brand name IBYRA, a pioneering PARP inhibitor designed to target specific genetic mutations. This strategic move aims to provide a more personalized and effective approach to combating various types of cancers, including breast, ovarian, prostate, and pancreatic cancers, which collectively affect nearly 275,000 patients in India each year, according to Globocan 2022 data.

IBYRA represents the next generation of targeted therapy, specifically for patients diagnosed as HRD positive or with a BRCA mutation. This group, crucially in need of PARP inhibitors, can now benefit from a treatment that significantly delays disease progression, marking a significant step forward in precision medicine.

Zydus has taken a holistic approach to patient care by partnering with MedGenome, facilitating comprehensive HRD testing to ensure that the right patients receive this cutting-edge treatment. Remarkably, the cost of a year-long treatment with IBYRA has been capped at Rs. 3 lakhs, a fraction of the cost compared to the innovator’s price of approximately Rs. 72 lakhs. This pricing strategy underscores Zydus’s commitment to making advanced cancer treatments more accessible and affordable to the Indian population.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, highlighted the impact of this launch, stating, “For patients newly diagnosed with these specific cancers, the right diagnosis and the right treatment early on can give them a big advantage in the fight against cancers. Our patient support focus in launching IBYRA helps them with both cutting-edge diagnosis for HRD positive cancer and precision therapy in the most affordable way. We believe this will reduce the disease burden for the patients in a significant way.”

Zydus’s introduction of IBYRA into the Indian market is a testament to the company’s leadership in oncology and its patient-centric approach. With a history of launching first-in-India biosimilars and therapies, Zydus continues to drive access and affordability in cancer care, ensuring that more patients can benefit from the latest advancements in treatment.

The launch of IBYRA by Zydus is a pivotal moment in the Indian healthcare sector, offering hope and advanced treatment options to thousands of cancer patients. By making PARP inhibitor therapy more affordable and accessible, Zydus is not only addressing the immediate needs of patients but also paving the way for future innovations in cancer treatment. This initiative is likely to have a profound impact on the quality of life for many, underscoring the importance of affordability and accessibility in the journey towards overcoming cancer.